A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF DEXPRAMIPEXOLE ADMINISTERED ORALLY FOR 52 WEEKS IN PARTICIPANTS WITH SEVERE EOSINOPHILIC ASTHMA (EXHALE-2)
- Registry ID
- AR-DEX-22-01
- Source registry
- HEALTH_CANADA
- Status
- Closed
- Study type
- INTERVENTIONAL
- Sponsor
- ARETEIA THERAPEUTICS, INC
- Start date
- 2024-02-27
- Completion date
- 2025-11-05
- Last update
- 2023-11-14
Conditions
Related clinical trials
- THE IMAGINE STUDY: A PHASE 3B OPEN LABEL, SINGLE ARM STUDY TO ASSESS THE EFFECT
OF DEPEMOKIMAB ON AIRWAY STRUCTURE AND FUNCTION IN ASTHMA WITH TYPE 2
INFLAMMATION CHARACTERIZED BY AN EOSINOPHILIC PHENOTYPE UTILIZING QUANTITATIVE
HIGH-RESOLUTION CT AND BRONCHOSCOPIC AIRWAY SAMPLING IN A SUB-STUDY
- BRISOTE: A MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP, ACTIVE-CONTROLLED, PHASE 3B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BENRALIZUMAB 30 MG SC IN EOSINOPHILIC ASTHMA PATIENTS UNCONTROLLED ON MEDIUM-DOSE INHALED CORTICOSTEROID PLUS LONG-ACTING B2-AGONIST
- A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MULTI-CENTRE, NON-INFERIORITY STUDY ASSESSING EXACERBATION RATE, ADDITIONAL MEASURES OF ASTHMA CONTROL AND SAFETY IN ADULT AND ADOLESCENT SEVERE ASTHMATIC PARTICIPANTS WITH AN EOSINOPHILIC PHENOTYPE TREATED WITH GSK3511294 COMPARED WITH MEPOLIZUMAB OR BENRALIZUMAB
- EFFICACY OF RESLIZUMAB DOSE ESCALATION IN PATIENTS WITH SEVERE ASTHMA AND PERSISTENT SPUTUM EOSINOPHILIA DESPITE STANDARD DOSE THERAPY.
- A PHASE 4, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFECT OF BENRALIZUMAB ON STRUCTURAL AND LUNG FUNCTION CHANGES IN SEVERE EOSINOPHILIC ASTHMATICS (CHINOOK)
- A MECHANISTIC PILOT OPEN-LABEL STUDY TO EVALUATE THE EFFECT OF BENRALIZUMAB ON AIRWAY FUNCTION AND INFLAMMATION IN PATIENTS WITH SEVERE, POORLY-CONTROLLED EOSINOPHILIC ASTHMA USING INHALED HYPERPOLARIZED 129XE MRI (AERFLO)
View on source registry